Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Superficial thrombophlebitis

Essential points for quick revision.

Saved on this device
!
Deep extension or embolism

Superficial vein thrombosis can coexist with deep vein thrombosis or pulmonary embolism and becomes a higher-risk anatomical event when it approaches a deep venous junction.

Action: Arrange whole-leg duplex promptly; if DVT, PE, or SVT less than 3 cm from a deep venous junction is identified, escalate to therapeutic anticoagulation assessment. Treat an exact 3 cm measurement as a specialist product-scope boundary.

Synopsis

Diagnose lower-limb superficial vein thrombosis, exclude associated deep thrombosis, and choose anticoagulation from thrombus length, junction distance and patient risk.

  • Suspected lower-limb superficial vein thrombosis needs whole-leg duplex to measure extent and junction distance and to exclude asymptomatic, non-contiguous or contralateral DVT.
  • ESVS places SVT less than 3 cm from a deep venous junction in the therapeutic anticoagulation branch; exactly 3 cm is a specialist product-scope boundary, not an automatic fondaparinux prescription.
  • For isolated SVT at least 5 cm long and at least 3 cm from a deep junction, ESVS recommends fondaparinux 2.5 mg subcutaneously once daily for 45 days; the UK Arixtra licence is stricter and requires more than 3 cm from the saphenofemoral junction.

Key red flags

Breathlessness, pleuritic chest pain, haemoptysis, syncope, hypoxia or hypotension requires urgent assessment for pulmonary embolism.

Whole-leg swelling, deep venous tenderness or marked unilateral oedema suggests associated DVT, but absence of these signs cannot safely exclude an asymptomatic DVT.

Thrombus less than 3 cm from the saphenofemoral or saphenopopliteal junction enters the ESVS therapeutic branch; an exact 3 cm distance needs specialist selection because ESVS and the UK Arixtra licence meet at different boundaries.

Fever, rapidly spreading erythema, purulence, hypotension, severe pain or tissue crepitus suggests infection or necrotising disease rather than sterile superficial venous inflammation.

Active bleeding, severe renal impairment, very low body weight, pregnancy, thrombocytopenia or interacting antithrombotic treatment requires individual anticoagulant review before prescribing.

Investigation priorities

01
Bilateral whole-leg duplex ultrasoundFirst step

Confirm superficial thrombus, measure its full length and distance from deep junctions, and inspect deep veins for synchronous thrombosis.

Management branches

Acute decision pathwayDuplex-defined lower-limb SVT

Use after a painful superficial cord is suspected and before choosing any anticoagulant intensity or duration.

  1. Arrange bilateral whole-leg duplex to exclude DVT and record SVT vein, length and exact distance from the nearest deep venous junction.
  2. If DVT or PE is present, use the relevant VTE pathway; if SVT lies less than 3 cm from a deep junction, arrange therapeutic anticoagulation assessment.

Key medicines

Fondaparinux sodiumFor eligible isolated lower-limb SVT, inject 2.5 mg subcutaneously once daily for 45 days; the UK licence permits a minimum 30 and maximum 45 days in high-risk patients.Contraindicated at CrCl below 20 mL/min; reduce to 1.5 mg daily at CrCl 20–50 though SVT evidence is unstudied. Not recommended for SVT below 50 kg or severe hepatic impairment; avoid active bleeding and use in pregnancy only if clearly necessary.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom